Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(5):467–472. doi: 10.1111/j.1349-7006.2003.tb01466.x

Chemosensitivity of human pancreatic carcinoma cells is enhanced by IkBα super‐repressor

Toshiyuki Sato 1, Hiroki Odagiri 1,✉, Shojiro‐Kazunori Ikenaga 1, Masateru Maruyama 1, Mutsuo Sasaki 1
PMCID: PMC11160233  PMID: 12824895

Abstract

Pancreatic cancer has an unfavorable prognosis; surgery and chemotherapy at present have only limited value. To improve the prognosis of pancreatic cancer, effective non‐surgical therapy is necessary. NF‐kB is reported to be related to resistance to apopto‐sis, but its role in Chemosensitivity remains controversial. We examined the effects on Chemosensitivity of inhibition by induction of the super‐repressor IkBα in pancreatic cancer cell lines, BxPC‐3, Capan‐1 and Panc‐1. IkBα protein was transduced by infection of adenovirus vector AxCAhlkBδN. Sensitivity to VP‐16 and doxorubicin was increased significantly by IkBα induction in all three pancreatic cell lines. To investigate molecular events during IkBα induction, we examined the changes in expression of drug‐resistance‐related genes by real‐time RT‐PCR and those in apoptosis‐related genes by cDNA microarray. There was no common change of gene expression before and after IkBα induction among the three pancreatic cancer cell lines, except for mdm2. Further examination of other genes is necessary for a better understanding of the molecular mechanisms of enhancement of Chemosensitivity through IkBα induction. However, we have confirmed that IkBα induction leads to an increase of Chemosensitivity of pancreatic cancer. Many problems remain before clinical application of this adenoviral system will be feasible, but our results may ultimately lead to an improved therapy of pancreatic cancer. (Cancer Sci 2003; 94: 467–472)

References

  • 1. Matsuno M. Multi‐institutional registration and follow‐up studies of patients with pancreatic cancer throughout the country (Summary of cases in 1999). J Jpn Pancreas Soc 2001; 16: 115–47. [Google Scholar]
  • 2. Klinkenbijl JH, Jeekel J, Sahmoud T, Van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, De Wit LT, Hennipman A, Wils J. Adjuvant radiotherapy and 5‐fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776–84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Neoptolemos JP, Baker P, Beger H, Link K, Pederzoli P, Bassi C, Dervenis C, Friess H, Buchler M. Progress report. A randomized multicenter European study comparing adjuvant radiotherapy, 6‐mo chemotherapy, and combination therapy vs no‐adjuvant treatment in respectable pancreatic cancer (ESPAC‐1). Int J Pancreatol 1997; 21: 91–104. [DOI] [PubMed] [Google Scholar]
  • 4. Shinoura N, Yamamoto N, Yoshida Y, Fujita T, Saito N, Asai A, Kirino T, Hamada H. Adenovirus‐mediated gene transduction of IKB or IKB plus Bax gene drastically enhances tumor necrosis factor (TNF)‐induced apoptosis in human gliomas. Jpn J Cancer Res 2000; 91: 41–51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Wang CY, Cusack JC Jr, Liu R, Baldwin A Jr. Control of inducible chemoresistance: enhanced anti‐tumor therapy through increased apoptosis by inhibition of NF‐KB. Nat Med 1999; 5: 412–7. [DOI] [PubMed] [Google Scholar]
  • 6. Arlt A, Vorndamm J, Breitenbrouch M, Folsh UR, Kalthoff H, Schmidt WE, Schafer H. Inhibition of NF‐KB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogens 2001; 20: 859–68. [DOI] [PubMed] [Google Scholar]
  • 7. Feig BW, Lu X, Hunt KK, Shan Q, Yu D, Pollock R, Chiao P. Inhibition of transcription factor nuclear factor‐K B by adenoviral‐mediated expression of IKBαM results in tumor cell death. Surgery 1999; 126: 399–405. [PubMed] [Google Scholar]
  • 8. Patel NM, Nozaki S, Shortle NH, Bhat‐Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet RJ, Sledge GW, Nakshatri H. Paclitaxel sensitivity of breast cancer cells with constitutively active NF‐KB is enhanced by IKBα super‐repressor and parthenolide. Oncogene 2000; 19: 4159–69. [DOI] [PubMed] [Google Scholar]
  • 9. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNFa‐induced apoptosis by NF‐KB. Science 1996; 274: 787–9. [DOI] [PubMed] [Google Scholar]
  • 10. Wang CY, Mayo MW, Baldwin AS Jr. TNF‐ and cancer therapy‐induced apoptosis: potentiation by inhibition of NF‐KB. Science 1996; 274: 784–7. [DOI] [PubMed] [Google Scholar]
  • 11. Bentires‐Alj M, Hellin AC, Ameyar M, Chouaib S, Merville MP, Bours V. Stable inhibition of nuclear factor KB in cancer cells does not increase sensitivity to cytotoxic drugs. Cancer Res 1999; 59: 811–5. [PubMed] [Google Scholar]
  • 12. Tietze MK, Wuestefeld T, Paul Y, Zender L, Trautwein C, Manns MP, Kubicka S. IKBα gene therapy in tumor necrosis factor α‐ and chemotherapy‐mediated apoptosis of hepatocellular carcinomas. Cancer Gene Ther 2000; 7: 1315–23. [DOI] [PubMed] [Google Scholar]
  • 13. Cai Z, Korner M, Tarantino N, Chouaib S. IKBα over‐expression in human breast carcinoma MCF7 cells inhibits nuclear factor‐KB activation but not tumor necrosis factor α‐induced apoptosis. J Biol Chem 1997; 272: 96–101. [DOI] [PubMed] [Google Scholar]
  • 14. Li Y, Zhang W, Mantell LL, Kazzaz JA, Fein AM, Horowitz S. Nuclear factor‐KB is activated by hyperoxia but does not protect from cell death. J Biol Chem 1997; 272: 21646–9. [DOI] [PubMed] [Google Scholar]
  • 15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55–63. [DOI] [PubMed] [Google Scholar]
  • 16. Beg AA, Baltimore D. An essential role for NF‐KB in preventing TNFα‐induced cell death. Science 1996; 274: 782–4. [DOI] [PubMed] [Google Scholar]
  • 17. Sheper RJ, Broxterman HJ, Sheffer GL, Kaaijk P, Dalton WS, Van Heijningen TH, Van Kalken CK, Slovak ML, de Vries EG, van der Valk P. Overexpression of a M(r) 110,000 vesicular protein in non‐P‐glycoprotein‐mediated multidrug resistance. Cancer Res 1993; 53: 1475–9. [PubMed] [Google Scholar]
  • 18. Cole SP, Sparks KE, Eraser K, Loe DW, Grant CE, Wilson GM, Deeley RG. Pharmacological characterization of multidrug resistant MRP‐transfected human tumor cells. Cancer Res 1994; 54: 5902–10. [PubMed] [Google Scholar]
  • 19. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deelwy RG. Overexpression of multidrug resistance‐associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994; 54: 357–61. [PubMed] [Google Scholar]
  • 20. Muller M, Meijer C, Zaman GJ, Borst P, Scheper RJ, Mulder NH, De Vries ED, Jansen PL. Overexpression of gene encoding the multidrug resistance‐associated protein results in increased ATP‐dependent glutathione S‐conjugate transport. Proc Natl Acad Sci USA 1994; 91: 13033–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Sceffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ. The drug resistance‐related protein LRP is the human major vault protein. Nat Med 1995; 1: 578–82. [DOI] [PubMed] [Google Scholar]
  • 22. Kudoh K, Ramanna M, Racatn R, Elkahloun AG, Bittner ML, Meltzer PS, Trent JM, Dalton WS, Chin KV. Monitoring the expression profiles of doxorubicin‐induced and doxorubicin‐resistant cancer cells by cDNA microarray. Cancer Res 2000; 60: 4161–6. [PubMed] [Google Scholar]
  • 23. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y, Tamaoki N, Nomura T, Kitahara O, Yanagawa R, Hirata K, Nakamura Y. Genome‐wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human colon cancer xenografts to anticancer drugs. Cancer Res 2000; 62: 518–27. [PubMed] [Google Scholar]
  • 24. Hochhauser D, Valkov, Gump JL, Wei I, O'Hare C, Hartley J, Fan J, Bertino JR, Banerjee D, Sullivan DM. Effects of wild‐type p53 expression on the quantity and activity of topoisomerase IIα and β in various human cancer cell lines. J Cell Biochem 1999; 75: 245–57. [DOI] [PubMed] [Google Scholar]
  • 25. Huang LC, Clarkin KC, Wahl GM. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53 dependent G1 arrest. Proc Natl Acad Sci USA 1996; 93: 4827–32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Ikeguchi M, Ueda T, Fukuda K, Yamaguchi K, Tsujitani S, Kaibara N. Expression of murine double minute gene 2 oncoprotein in esophageal squamous cell carcinoma as a novel marker for lack of response to chemora‐diotreatment. Am. J Clin Oncol 2002; 25: 454–9. [DOI] [PubMed] [Google Scholar]
  • 27. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I. p53 stabilization is decreased upon NF‐KB activation: a role for NF‐KB in acquisition of resistance to chemotherapy. Cancer Cell 2002; 1: 493–503. [DOI] [PubMed] [Google Scholar]
  • 28. Gu L, Findley HW, Zhou M. MDM2 induces NF‐KB/p65 expression transcriptionally through Sp1‐binding sites: a novel, p53‐independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood 2002; 99: 3367–75. [DOI] [PubMed] [Google Scholar]
  • 29. Randolph J, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX‐015 with intravenous gemcitabin in unresectable pancreatic carcinoma. Clin Cancer Res 2003; 9: 555–61. [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES